Research

Retina Division

Home > Research > Retina Division

Clinical Faculty

Frederick H. Davidorf, MD

L. Carol Laxson, MD

Alan Letson, MD

Retina Fellow(s)

Research Faculty

Mohamed Abdel-Rahman, MD, PhD

Research Coordinator(s)

Jill Salerno
Phone: 614-652-2620
Kathryne McKinney
Phone: 614-652-2603

Now Recruiting!

CATT Study
Do you have newly diagnosed wet Age-related Macular Degeneration (AMD)?

AMD is leading cause of blindness in patients over 50
Study compares Avastin© vs. Lucentis©; both treat AMD
Study patients must have insurance

Nevanac© Study
Are you a diabetic patient about to undergo cataract surgery?

After cataract surgery, diabetics often develop Diabetic Macular Edema (DME)
DME is swelling in the back of the eye that causes blurred vision
Nevanac© may prevent DME
Patients paid up to $280 over 3 months

HARBOR Study
Do you have untreated wet Age-related Macular Degeneration (AMD)?

AMD is leading cause of blindness in patients over 50
Lucentis© treats AMD
Lucentis© and office visits free of charge
Patients paid up to $2000 over 2 years

Call Kathy McKinney or Jill Salerno at 293-5287 or mckinney.5@osu.edu and jill.salerno@osumc.edu.

Current Clinical Trials

Nevenac: A Clinical Safety and Efficacy Comparison of NEVENAC© 0.1% to vehicle Following Cataract Surgery in Diabetic Retinopathy Patients. TM Mauger (PI), RH Lembach, A Tandon, R Kuennen, J Christoforidis, AD Letson, FH Davidorf, S Chang, P Kurz, C Cebulla. Alcon Pharmaceuticals, 2009-10.

HARBOR: A Phase III, Double-Masked, Multicenter, Randomized, Active Treatment-Controlled Study of the Efficacy and Safety of 0.5 mg and 0.2 mg Ranibizumab Administered Monthly or On an As-Needed Basis (PRN) in patients with subfoveal neovascular age-related macular degeneration. J Christoforidis (PI), AD Letson, FH Davidorf, S Chang, P Kurz, C Cebulla. Genentech Pharmaceuticals, 2009-2011.

DRCR J: Ranibizumab vs. Triamcinolone vs. Sham as an adjunctive therapy for patients with PDR or severe Non-Proliferative Diabetic Retinopathy (NPDR) who require Panretinal Photocoagulation (PRP). J Christoforidis(PI), AD Letson, FH Davidorf, S Chang. National Institute of Health (NEI), 2008-09.

RIDE: Phase III, double-masked, multicenter, randomized, sham-controlled study of the efficacy and safety of ranibizumab injection in subjects with clinically significant macular edema with center involvement secondary to diabetes mellitus. AD Letson (PI), J Christoforidis, FH Davidorf, R Deasy. Genentech Pharmaceuticals, 2007-09.

AREDS II: Multi-center, randomized trial of Lutein, Zeaxanthin, and omega-3 fatty acids in age-related macular degeneration. AD Letson (PI), RB Chambers, J Christoforidis, FH Davidorf, LC Laxson. National Eye Institute (NEI)/EMMES Corporation, 2006–12.

CATT: Comparison of Age-related Macular Degeneration Treatments Trials Frederick H. Davidorf, MD (PI), Alan Letson, MD, John Christofordis, MD, Susie Chang, MD. National Institute of Health (NEI), 2007-10.

Completed Clinical Trials

K Osei,(PI), E Craig, FH Davidorf, AD Letson. Actions to control cardiovascular risk factors in diabetes eye study (ACCORD), National Institute of Health (NEI), 2004-09.

AD Letson (PI), FH Davidorf, RB Chambers, LJ Chorich. A Phase IV, open label, multi-center, trial of maintenance intravitreous injections of Macugen® (pegaptanib sodium) given every 6 weeks for 48 weeks in subjects with subfoveal neovascular age-related macular degeneration (AMD) initially treated with a modality resulting in maculopathy improvement (LEVEL), OSI/Eyetech Pharmaceuticals, 2006-08.

FH Davidorf (PI), RB Chambers, LJ Chorich, J Christoforidis. Intravitreal triamcinolone for diabetic macular edema, (DRCR B). Diabetic Retinopathy Clinical Research Network, National Eye Institute (NEI), 2004-08.

FH Davidorf (PI), RB Chambers, R Deasy. An open-label, multi-center extension study to evaluate the safety and tolerability of ranibizumab in subjects with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) who have completed the treatment phase of a genentech-sponsored ranibizumab study (HORIZON), Genentech Pharmaceuticals, 2006-08.

J Christoforidis(PI), AD Letson, FH Davidorf, S Chang. A Phase III Multicenter, Randomized, Sham Injection-Controlled Study of the Efficacy and Safety of Ranibizumab Injection Compared with Sham in Subjects with Macular Edema Secondary to Branch Retinal Vein Occlusion (BRAVO), Genentech, 2008-09.

J Christoforidis(PI), AD Letson, FH Davidorf, S Chang. A Phase III Multicenter, Randomized, Sham Injection-Controlled Study of the Efficacy and Safety of Ranibizumab Injection Compared with Sham in Subjects with Macular Edema Secondary to Central Retinal Vein Occlusion (CRUISE), Genentech, 2008-09.

RB Chambers (PI), FH Davidorf. Phase IIIb randomized, double-masked, sham controlled, multi-center study comparing photodynamic therapy with Verteporfin (Visudyne) plus two different dose regimens of intravitreal pegaptanib (Macugen) in patients with subfoveal choroidal neovascularization secondary to AMD (VERITAS) Novartis Pharmaceuticals, 2005–08.

RB Chambers (PI), FH Davidorf, LJ Chorich. A phase IIIb, single masked, multicenter, randomized study to evaluate the safety and tolerability of ranibizumab in naïve and previously treated subjects with choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) (SAILOR). Genentech Pharmaceuticals, 2005–07.

RB Chambers (PI), LJ Chorich, FH Davidorf, AD Letson. Safety assessment of intravitreal Lucentis for AMD: a phase IIIb multicenter study to evaluate the safety and tolerability of ranibizumab (0.3 mg and 0.5 mg) in naïve and previously treated subjects with CNV secondary to AMD (SAILOR II), Genentech Pharmaceuticals, 2006-07.

FH Davidorf (PI), LJ Chorich, RB Chambers. Phase IIIb, Multi-center, randomized, double masked, sham injection controlled study of the efficacy and safety of rhuFab V2 (ranibizumab) in subjects with subfoveal choroidal neovascularization (CNV) with or without classic CNV secondary to age-related macular degeneration (PIER), Genentech Pharmaceuticals, 2004-06.

FH Davidorf (PI), RB Chambers, LJ Chorich, J Christoforidis. Observational study of diabetic macular edema after PRP, (DRCR F) Diabetic Retinopathy Clinical Research Network, National Eye Institute (NEI), 2006-07.

FH Davidorf (PI), RB Chambers, LJ Chorich, J Christoforidis. Sub-clinical diabetic macular edema with OCT, (DRCR G) Diabetic Retinopathy Clinical Research Network, National Eye Institute (NEI), 2006-2007.

FH Davidorf (PI), RB Chambers, LJ Chorich. Peribulbar triamcinolone for diabetic macular edema, (DRCR E) Diabetic Retinopathy Clinical Research Network, National Eye Institute (NEI), 2004-07.

FH Davidorf (PI), RB Chambers, LJ Chorich. Temporal variation in optical coherence tomography measurments of retinal thickening in diabetic macular edema. (DRCR C) Diabetic Retinopathy Clinical Research Network, National Eye Institute (NEI), 2004-07.

FH Davidorf (PI), RB Chambers, LJ Chorich. Pilot laser photocoagulation for diabetic macular edema, (DRCR A) Diabetic Retinopathy Clinical Research Network, National Eye Institute (NEI), 2004-07.

FH Davidorf (PI), RB Chambers. Complications of age-related macular degeneration prevention trial (CAPT), National Eye Institute (NEI), 2002–07.

FH Davidorf (PI), RB Chambers, LJ Chorich. Dexamethasone in subjects with central retinal vein occlusion or branch retinal vein occlusion with diabetic macular edema (POSURDEX). Allergan Pharmaceuticals, 2004-07.